Introduction
Since the mid -19 th century, our forebears in pathology noticed that tumors arise as embryo-like cells. This was based on the observed similarity between embryonal tissue and cancer tissue [1] . Cancer cells have reverted to an undifferentiated state and shared the features of embryo cells. Another hypothesis was that the real cause of tumor formation is to be sought in a defect or irregularity of the embryonic rudiment (Julius Cohnhein, 1889). The latter hypothesis was confirmed when stem cells emerged.
One important feature of embryonal cells is their resistence to xenobiotics, a feature which ensures the natural protection of the embryo against various external noxious substances. Therefore breaking down this resistance could contribute to overcoming the MDR which is now a major impediment in the successful treatment of cancer. In short, as embryo cells are similar to cancer cells, they may serve as a useful tool in the study of MDR.
Multi-drug-resistance (MDR)
Multi-drug-resistance (MDR) is now a serious obstacle in the treatment of patients with different types of tumors.
MDR is the ability of tumor cells to resist the cytotoxic effects of a variety of structurally and functionally unrelated drugs. There are a large number of cellular factors contributing to drug resistance including the activation of de-toxifying enzymes, activation of DNA repair mechanisms, alterations in drug-induced apoptosis and increased drug efflux due to overexpression of membrane transporters [2] . In reality, drug resistance is not a single resistance mechanism but involves several simultaneously. Additionally, each tumor has its own unique resistance factor profile.
Multi-drug-resistance (MDR) pumps
MDR pumps, in other words, transmembrane proteins that belong to the ATP-binding cassette (ABC) transporter superfamily, play an important role in MDR. These use energy from ATP to transport various molecules across cell membranes. Their primordial role is to protect the organism from natural toxins by escorting them out of the cell. In cancer cells, MDR pumps cause drug resistence by the efflux of cell-killing chemotherapy molecules. These pumps are active in a broad spectrum of human cancers, including lymphoma, leukemia, breast, lung and ovarian cancers. The more MDR pumps cancer cells have the less effective chemotherapy is likely to be [3] .
There are 48 human ABC transporters which are classified into seven distinct subfamilies of proteins called ABCA-G. Three have been found in nearly all of MDR tumor cells in both human and rodent tissues. These include ABCB1/PGP/ MDR1, ABCC1/MRP1 and ABCG2/MXR/BCRP [4] . The first is most often specified as P-glycoprotein (P-gp). It is a 170 kDa ATP-dependent efflux pump encoded by the mdr1 gene [5, 6] located on chromosome 7q21.1 [7] . Mice have two homologues of ABCB1 (Abcb1a coding mdr1a and Abcb1b coding mdr1b). It is expressed in many normal tissues such as adrenal gland, kidney, liver, brain, intestine and hematopoietic stem cells where it has an excretory, protective or hormone handling role [8, 9] . Overexpression of this protein is sufficient to confer drug resistance [10] . It is possible to inhibit the function of P-gp by specific inhibitors but with the loss of its natural function. The second pump is known as multidrug resistance associated protein 1 (MRP1). It is located on chromosome 16p13.1. Yet, unlike P-gp, MRP1 operates with drugs or biologically active endogenous substrates conjugated with glucuronide, sulfate or glutathione [11] . Additionally, four homologues of MRP1 have been identified: MRP2/cMOAT (encoded by ABCC2), MRP3 (encoded by ABCC3), MRP4/MOATB (encoded by ABCC4) and MRP5/MOATC (encoded by ABCC5). Their physiological role is still unknown, however it is possible that they play role in cellular detoxification process and are involved in mediating drug resistence, too [12] . The third pump is located on chromosome 4q22 and has been identified in multidrug-resistant colon cancer cell line and breast cancer cell line that does not overexpress ABCB1 or ABCC1 [13] . Recently Krishnamurthy et al. suggested that expression of this pump is induced by hypoxia and this regulation involves the hypoxia-inducible transcription factor complex HIF-1 [14] .
Expression patterns of MDR pumps in embryonal/fetal tissues
The main MDR pumps described above have also been found in embryonal/fetal tissues. A high level of mouse mdr1b was found in the endometrium and placental trophoblast of the pregnant uterus. It is assumed that its physiological role is to protect the fetus against xenobiotics during pregnancy [15] . P-gp is present in oocytes and early cleavage embryos where it mediates a self-protecting function during the time of germ cell maturation and early pre-implantatory development [16] . Kalken et al. studied the expression of P-gp in fetal tissues obtained during different developmental stages using immunohistochemistry. They compared the distribution of this protein in fetal and adult tissues. Differences were found in adrenal, intestine, respiratory epithelium, and brain capillaries [17] . Mdr1 mRNA begins to be expressed in the thymus of chicken embryo from day 12 until hatching but in the bursa from day 14 to day 17 of embryonic life [18] . Matsuoka et al. studied expression and localization of P-gp in the rat brain during development. It is localized in brain capillaries and was first detected on postnatal day 7 and then gradually increased to reach a plateau in the adult brain [19] . While the level of rat mdr1a and mdr1b transcript increases, the level of Mrp1 transcript is the same in all tissues during rat ontological development [20] . The high levels of ABCG2 in a subpopulation of hematopoetic stem cells [21] and the trophoblast cells of the placenta [22] suggest that it can transport compounds into fetal blood and remove toxic drugs and metabolites.
Multi-drug-resistance (MDR) and peroxisome proliferator-activated receptors (PPARs)
Recently a few studies have reported that the expression level of some MDR proteins can be regulated by activation or deactivation of PPAR receptors (see below).
Peroxisome proliferator-activated receptors (PPARs)
PPARs are steroid nuclear receptors which belong to the same superfamily as thyroid, retinoid and vitamin D receptors [23] . They regulate diverse biological processes such as lipid and carbohydrate metabolism, development, differentiation, apoptosis, neoplastic transformation, inflammation and the regeneration of tissues. Their ligands are thus becoming a good tool in the treatment of some serious human conditions such as obesity, type two diabetes, arteriosclerosis, infertility and cancer.
PPARs are transcription factors that regulate the expression of specific genes in a ligand-dependent manner. They were first described at the beginning of 1990's as the receptor activated by rodent hepatocarcinogens that cause peroxisome proliferation [24] . Three new members of these receptors (PPAR-α, PPAR-β/δ and PPAR-γ) were later found in the Xenopus frog and these had hypolipidemic effects during stimulation of peroxisomal degradation of fatty acids [25] . They require heterodimerization with the retinoid X receptor to start transcriptional activity [26] . They consist of 6 functional domains designated A to F. The N-terminal A/B region has a variable length and an autonomous activation function (AF-1). The most conserved C-domain is DNA-binding domain (DBD) that consists of two zinc-finger-like motifs characteristic for nuclear receptors. The D domain is a variable hinge. The multifunctional E domain encompasses the ligandbinding domain (LBD), a second activation function (AF-2) critical for transcriptional activation, a dimerization domain and region involved in nuclear localization. The F domain is present only in some nuclear receptors (absent in PPARs) [23] . In the presence of an agonist, DBD is bound to promoter sequences called the peroxisome proliferator response elements (PPRE) and this triggers expression of specific genes. PPREs are composed of two direct repetitions (DR-1) of the consensus sequence AGGTCA with a single nucleotide spacing between the two repeats [27] . Natural ligands of PPARs include fatty acids and eicosanoids. Synthetic ligands include lipid lowering drugs (like fibrates) and insulin sensitisers (like thiazolidinediones). PPARs do not contact the basal transcription machinery directly but require interaction with co-regulator complexes such as coactivator for stimulation or a co-repressor for inhibition of target gene expression [28] .
PPAR isoforms and their localization
The PPAR subfamily consists of the three isoforms: PPAR-α, PPAR-β/δ and PPAR-γ. Each is coded by different genes located on different chromosomes. The receptors differ in their physiological roles, rate of expression in different tissues and ligand specificity. All three isotypes are widely expressed in somatic cells, in the developing fetus and in the germ cells of the ovary and testis. In rat PPAR-β/δ is expressed in the early phase of prenatal development with a marked peak at days 13,5-15,5, whereas PPAR-α and PPAR-γ appear later in the tissues where they will continue to be expressed in adulthood [30] , with the exception of a transient expression in the CNS and the epidermis. PPAR-α was detected in tissues with a high catabolic rate (increased β-oxidation) of fatty acids and high peroxisome-dependent activities (liver, heart, kidney, intestine and brown adipose tissue) [31] . PPAR-β/δ has the broadest expression pattern. The levels of expression of this isotype depend on the extent of cell proliferation and differentiation. It has been found in skin, gut, placenta, skeletal muscle, adipose tissue and brain [32] . PPAR-γ has been the most studied. It is the most divergent isotype expressed as the two isoforms -γ1 and -γ2, that differ at their N terminus. Each isoform is expressed by a different promoter. PPARγ2 is found in high levels in different adipose tissues [33] , whereas PPARγ1 has been detected in gut, brain, vascular cells and specific types of immune and inflammatory cells [34] . PPAR-γ has also been found in the granulosa cells that surround and support the maturing oocyte. This isotype is a negative regulator of follicular growth and differentiation. Its activation suppresses follicle development [35] . PPAR-β/δ and PPARγ have a crucial role in the placenta formation. Homozygote disruption of these two isotypes results in the death of the fetus by day 10 of development [36, 37] .
The concept of the regulation of MDR expression by PPAR ligands
Generally the concept of the regulation of MDR expression by PPAR ligands has been postulated by several autors and here we summarize the main known relationships between these groups of proteins.
PPAR-α agonists and Bcrp/Abcg2, MRP1, Mdr1a
Hirai et al. compared the expression level of some ABC transporters after treating mice with a normal diet and diet containing PPAR-α agonists. The expression of Bcrp/Abcg2 was up-regulated, MRP1 down-regulated while the expression of Mdr1a remained unchanged [38] .
PPAR-α agonist and MRP3, MRP4
Moffit et al. noticed increased levels of mRNAs and proteins of liver Bcrp, Mrp3 and Mrp4 in mice after clofibrate (PPAR-α agonist) treatment [39] . Also Maher et al. found that perfluorooctanoic acid and perfluorodecanoic acid (PFDA) increase expression of hepatic Mrp3 and Mrp4 mRNA. The presence of several direct repeat-1 elements (DR-1) of PPRE in the Mrp3 and Mrp4 5' regulatory regions suggest that PPAR-α may regulate these two transporters directly. MRP3 and MRP4 transporters can be also regulated by another transcription factor called NF-E2-related factor-2 (Nrf2). It is activated by PFDA directly or due to PPAR-α-dependent activation of drug-metabolizing enzymes [40] .
PPAR-γ agonists and ABCG2
Szatmari et al. demonstrated that PPAR-γ directly and transcriptionally induces the ABCG2 expression in human monocyte-derived dendritic cells and myeloid leukemia cell line MM6. They identified and characterized a 150-base pair long conserved enhancer region, containing three functional PPAR response elements (PPRE), upstream of the human ABCG2 gene. All three PPRE contain direct repeat (DR-1) motifs and are able to at the end of the sentence bind PPAR-γ/RXR heterodimers [41] .
PPAR-γ agonists and stroma
Hafner et al. supposed that PPAR-γ agonists influence stroma functions in cancer, too. They affect in particular angiogenesis but they also affect the immune response and they have direct anti-tumor effects [42] .
TNF-α and MDR1, PPAR-α
Wang et al. noticed that tumor necrosis factor-α (TNF-α) could induce down-regulation of MDR1 and up-regulation of PPAR-α and in this way enhance cytotoxicity by apoptosis in HepG2/ADM cells [43] .
PPARs and Hedgehog (Hh) signalling pathway
However, not all above mentioned relationships explain signalling crosstalk between MDR/PPARs pathways. Based on a few studies we hypothesize that Hedgehog (Hh) signalling pathway may connect these two mentioned upwards. Sims-Mourtada noticed that Hh pathway activation induces expression of two ABC transporter proteins: ABCB1/PGP/MDR1 and ABCG2/ MXR/BCRP [44] . Varnat et al. noticed that PPAR-β/δ regulate Paneth cell differentiation and homeostasis by down-regulating the expression of Indian hedgehog (Ihh) [45] . Additionally, Fontaine et al. found that Hedgehog signalling pathway control adipocyte maturation by targeting PPAR-γ2 expression [46] . Also Kim et al. noticed that 20(S)-hydroxycholesterol inhibit adipogenic differentiation through a hedgehog-dependent mechanism and this is associated with inhibition of PPARγ expression [47] .
Conclusion
Based on these studies, we suggest that a detailed description of MDR regulation in embryos with particular focus on MDR/PPAR pathways could provide us with important information enabling us to target MDR in cancers using synthetic PPAR ligands.
